Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD (COSYCONET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01245933|
Recruitment Status : Active, not recruiting
First Posted : November 23, 2010
Last Update Posted : September 16, 2020
The purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of COPD patients.
Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.
|Condition or disease|
|Chronic Obstructive Pulmonary Disease (COPD)|
|Study Type :||Observational|
|Actual Enrollment :||2741 participants|
|Official Title:||Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||September 2022|
- Change from baseline in BODE-Score at 18 months [ Time Frame: at initial visite, after 18, 36, 54, 72, 90 and 108 months ]The BODE-Score comprises BMI, airway obstruction, dyspnea and exercise capacity and is a good predictor for death in COPD patients. Progression is defined as a change in BODE-score by >=1 point over the observation period.
- COPD related mortality [ Time Frame: after 18 months ]The rate of mortality was elevated after 6, 18, 36, 54, 72, 90 and 108 months
- COPD related hospitalization [ Time Frame: after 18, 36, 54, 72, 90 and 108 months ]The rate of hospitalizations was elevated in every visit.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01245933
|Study Chair:||Claus Vogelmeier, Prof.||Philipps University Marburg Medical Center|